PharmTech Drug Digest 11.20
News|Articles|September 26, 2017

PTSM: Pharmaceutical Technology Sourcing and Management

  • PTSM: Pharmaceutical Technology Sourcing and Management-10-04-2017
  • Volume 12
  • Issue 10

Particle Analyzer Images Nanoparticles

The Nano-flow imaging particle analyzer from Fluid Imaging Technologies automatically image nanoparticles for identification.

The FlowCam Nano from Fluid Imaging Technologies reveals protein agglomerates, silicon oil droplets, glass shards, and other opaque, transparent, and translucent sub-visible particles with the high-resolution imagery needed for identification. The system uses a patented, oil immersion technology and provides digital images of particles ranging in size from 300 nm–30 µm.

Designed for analytical scientists, biochemists, and formulation scientists, the instrument was developed to find, expose, and identify nanoparticles in protein formulations and track the progression of protein agglomerates from individual, proteinaceous particles to the larger aggregates that can pose a threat to the safety, efficacy, stability, and longevity of parenteral bioformulations.

The company reports that the instrument may be used for USP <788> compliance testing methods for particulate matter by documenting the presence and type of nano-scale particles, which may cause failed test results.

Fluid Imaging Technologies, Inc.

 


Related to this article

Are Your Supplier Selection and Oversight Processes Robust Enough?
Despite best efforts to ensure a contract organization is following GMPs, a warning letter is issued by the FDA. Susan J. Schniepp, distinguished fellow at Nelson Labs, and Siegfried Schmitt, PhD, vice president, Technical at Parexel, provide advice for create a robust supplier selection and oversight system.
white pill capsule isolated on white background | Image Credit: ©F16-ISO100 -stock.adobe.com
PharmTech spoke with Chiara Bergerone, deputy CEO of Roquette’s Health & Pharma Solutions Business, about the company’s hydroxypropyl methylcellulose (HPMC) capsule, which was previewed at CPHI Milan 2026 in October.
Transitioning mRNA from R&D to GMP
Marco Pupo, PhD, innovation and development coordinator at Anemocyte, discusses the R&D-to-GMP transition and the changing shape of mRNA manufacturing facilities.